FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.

MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.

Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.

New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.

While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.

FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.

Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.